US Cancer Diagnostics Stock Surges 1.9 Trillion Won in a Day: What to Expect

Guardant Health Inc. (NASDAQ: GH) jumped 6.47% on April 4, closing at $135.25 per share—about KRW 200,000. Trading volume reached roughly 1.43 million shares, and its market capitalization swelled to $17.9 billion (approximately KRW 27 trillion), gaining about $1.2 billion (KRW 1.9 trillion) in a single day.

In its latest first‐quarter results, Guardant Health reported revenue of $301.7 million, a 48% increase year over year. Growth expectations have been further bolstered by the U.S. FDA’s approval of Guardant360® (Liquid CDx), a new blood-based genomic test offering 100-fold greater coverage than predecessor assays.

Guardant Health is a precision oncology diagnostics company that analyzes cancer-related genes from a single blood draw using liquid biopsy technology. Its portfolio includes Guardant360® for patients with metastatic cancer and Shield® for early colorectal cancer screening. Founded in 2012 by co-founders including Helmy Eltoukhy, the company went public on Nasdaq in 2018. It is now accelerating its push into the cancer-screening market through real-world data partnerships and multi-cancer early-detection research.